Events
December 8, 2025
ToxoTech founders to present at INA Toxins 2026 in Madrid

ToxoTech’s founders, Dr. Geoffrey Masuyer and Professor Pål Stenmark, will attend and present at INA Toxins 2026 in Madrid, one of the leading global conferences dedicated to botulinum neurotoxins and neuromodulator science. Both will showcase their latest research developments alongside experts from academia and industry.

The conference offers a valuable opportunity to exchange insights, discuss emerging scientific advances, and strengthen collaborations across the neuromodulator community.

Organisations or individuals wishing to connect with us during the event are welcome to reach out at info@toxotech.se to arrange a meeting.

Event details: https://www.neurotoxins.org/toxins-2026/

‍
Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Events
ToxoTech founders to present at INA Toxins 2026 in Madrid
Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.
Read article
News
ToxoTech and AAX Biotech and Join Forces to Advance Next-Generation Biotherapeutics
ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.
Read article
News
From toxins to therapies
Stockholm University researchers redesign botox
Read article
Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Events
ToxoTech founders to present at INA Toxins 2026 in Madrid
Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.
News
ToxoTech and AAX Biotech and Join Forces to Advance Next-Generation Biotherapeutics
ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.
News
From toxins to therapies
Stockholm University researchers redesign botox
Publications
New study reveals BoNT/A mutants with enhanced ganglioside binding and increased potency
Our collaborative research identifies BoNT/A variants with improved ganglioside engagement, providing insights into how receptor interactions shape potency and selectivity.
Supported by
Privacy Policy
+46 760 983 397
info@toxotech.se

Stockholm, Sweden
This component will only work on the published/exported site. Full documentation in Finsweet's Attributes docs.